Media stories about Azurrx Biopharm (NASDAQ:AZRX) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Azurrx Biopharm earned a news impact score of 0.23 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.0543635520255 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Azurrx Biopharm (AZRX) traded down 3.5095% during trading on Wednesday, hitting $3.0491. 8,764 shares of the stock traded hands. Azurrx Biopharm has a 52-week low of $2.85 and a 52-week high of $5.25. The company’s 50 day moving average price is $3.82 and its 200-day moving average price is $3.84. The stock’s market cap is $34.25 million.

Separately, HC Wainwright set a $8.00 price target on shares of Azurrx Biopharm and gave the stock a “buy” rating in a research note on Monday, October 23rd.

COPYRIGHT VIOLATION NOTICE: “Azurrx Biopharm (AZRX) Given News Sentiment Rating of 0.23” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at

About Azurrx Biopharm

AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.

Insider Buying and Selling by Quarter for Azurrx Biopharm (NASDAQ:AZRX)

Receive News & Stock Ratings for Azurrx Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azurrx Biopharm and related stocks with our FREE daily email newsletter.